[go: up one dir, main page]

MX2009008692A - Uso de sacarosa para suprimir la agregacion de proteina inducida por manitol. - Google Patents

Uso de sacarosa para suprimir la agregacion de proteina inducida por manitol.

Info

Publication number
MX2009008692A
MX2009008692A MX2009008692A MX2009008692A MX2009008692A MX 2009008692 A MX2009008692 A MX 2009008692A MX 2009008692 A MX2009008692 A MX 2009008692A MX 2009008692 A MX2009008692 A MX 2009008692A MX 2009008692 A MX2009008692 A MX 2009008692A
Authority
MX
Mexico
Prior art keywords
sucrose
mannitol
protein aggregation
induced protein
suppress
Prior art date
Application number
MX2009008692A
Other languages
English (en)
Inventor
Nicholas W Warne
Angela Kantor
Kin Ho
David C Sek
Donna L Luisi
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MX2009008692A publication Critical patent/MX2009008692A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona un método para suprimir la agregación de proteína inducida por manitol al proporcionar sacarosa a una formulación líquida que contiene una proteína. La presente invención también proporciona métodos para almacenar y preparar una formulación líquida que contiene una proteína y una combinación de manitol y sacarosa tal que la presencia de sacarosa suprime la agregación de proteína inducida por manitol.
MX2009008692A 2007-02-16 2008-02-15 Uso de sacarosa para suprimir la agregacion de proteina inducida por manitol. MX2009008692A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90180707P 2007-02-16 2007-02-16
PCT/US2008/054115 WO2008101179A2 (en) 2007-02-16 2008-02-15 Use of sucrose to suppress mannitol-induced protein aggregation

Publications (1)

Publication Number Publication Date
MX2009008692A true MX2009008692A (es) 2009-08-21

Family

ID=39402548

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008692A MX2009008692A (es) 2007-02-16 2008-02-15 Uso de sacarosa para suprimir la agregacion de proteina inducida por manitol.

Country Status (6)

Country Link
US (1) US20080200656A1 (es)
EP (1) EP2124890A2 (es)
JP (1) JP2010519220A (es)
CA (1) CA2677937A1 (es)
MX (1) MX2009008692A (es)
WO (1) WO2008101179A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ531407A (en) * 2001-08-06 2005-08-26 Robert Morvillo Integral reversing and trim deflector and control mechanism
BR112014028129A2 (pt) 2012-05-14 2017-06-27 Novo Nordisk As soluções de proteína estabilizadas
US11932699B2 (en) * 2017-09-07 2024-03-19 Jcr Pharmaceuticals Co., Ltd. Aqueous pharmaceutical composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215743A (en) * 1988-04-13 1993-06-01 Maninder Singh Tumor necrosis factor formulations
WO1993000807A1 (en) * 1991-07-03 1993-01-21 Cryolife, Inc. Method for stabilization of biomaterials
ATE216590T1 (de) * 1995-02-06 2002-05-15 Genetics Inst Arzneimittelformulierungen für il-12
MX9800684A (es) * 1995-07-27 1998-04-30 Genentech Inc Formulacion de proteinas liofilizadas isotonicas estables.
ATE454137T1 (de) * 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
WO2006014965A2 (en) * 2004-07-27 2006-02-09 Human Genome Sciences, Inc. Pharmaceutical formulation and process
KR20080071192A (ko) * 2005-11-22 2008-08-01 와이어쓰 면역글로불린 융합 단백질 제형

Also Published As

Publication number Publication date
US20080200656A1 (en) 2008-08-21
CA2677937A1 (en) 2008-08-21
JP2010519220A (ja) 2010-06-03
WO2008101179A8 (en) 2009-09-17
EP2124890A2 (en) 2009-12-02
WO2008101179A3 (en) 2008-12-24
WO2008101179A2 (en) 2008-08-21

Similar Documents

Publication Publication Date Title
MX2009008769A (es) Formulaciones de proteina que contienen sorbitol.
MX358886B (es) Macrociclos peptidomimeticos.
MX2015011898A (es) Compuestos de pirazolo y usos de los mismos.
IN2014DN10386A (es)
MX2017004896A (es) Uso de hexadeca-8, 15-dienal como producto quimico aromatico.
MX346936B (es) Metodo, composiciones y empaque para limpieza del intestino.
MX2013008390A (es) Preparacion de estructuras de metal-triazolato.
WO2012122383A3 (en) Pi3 kinase inhibitors and uses thereof
IL231591A0 (en) Converted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases
SG195086A1 (en) Compounds containing hydrido-tricyano-borate anions
PH12015502215B1 (en) Liquid creamer composition comprising oleosomes as replacement for oil and method of making the same
PH12013502348A1 (en) Liquid salt cleaning compositions
MX345458B (es) Composiciones antimicoticas para el tratamiento de piel y uñas.
NZ701463A (en) Anti-phytopathogenic composition
WO2015038736A3 (en) Formulations for cgrp receptor antagonists
MX2019013560A (es) Formulaciones con oxidacion reducida.
MX2013012337A (es) Composiciones y metodos.
MX2009008692A (es) Uso de sacarosa para suprimir la agregacion de proteina inducida por manitol.
MX370416B (es) Formulaciones con oxidacion reducida.
HK1255041A1 (zh) Fxia抑制剂的逆转剂
PH12014502323A1 (en) Oral formulation
WO2012174164A3 (en) Agonists of gpr131 and uses thereof
PT3068863T (pt) Processo dinâmico de eliminação parcial ou total de compostos organoalogenados contidos em bebidas, nomeadamente no vinho
GB201004677D0 (en) New salt
WO2013010644A3 (de) Bauelement

Legal Events

Date Code Title Description
FA Abandonment or withdrawal